Diego Pichardo, MD.
@DiegoPichardoMD
Mexican IMG | Neurosurgery Aspirant | Researcher
I feel truly grateful and blessed for the opportunity to start my first clinical position as a #Neurosurgery Preresidency Fellow in New York. Forever thankful to my mentors for their support and excited for the work ahead! 🙏🏼✝️
Wrapped up SNIS 22nd in Nashville — what a fantastic city! Great time catching up with friends and colleagues @SNISinfo #SNIS2025 #Nashville
Just Published in Operative Neurosurgery: @NeurosurgeryCNS In this multicenter collab of 157 patients, we report the experience of performing Middle Meningeal Artery Embolization (MMAE) with concomitant surgical evacuation as a single session for the treatment of symptomatic…
🧠 New publication in Epilepsia! During the evaluation of epileptic networks in drug-resistant epilepsy, SEEG-guided radiofrequency thermocoagulation can improve seizure burden and even result in seizure freedom in some patients! Work led by @PavelPichardoMD , under the guidance…

📢 New publication! Our latest article in Epilepsia Open evaluates the long-term outcomes of corpus callosotomy in adults with drug-resistant epilepsy. 🔹 73.8% of patients had a ≥50% seizure reduction at long-term follow-up (>3y). 🔹 Despite most studies presenting the…

Check out our long term experience with corpus callosotomy in adults at @INNNMVS. Great job @DiegoPichardoMD! Open access link: doi.org/10.1002/epi4.7…
Accelerated titration programming in VNS implantation for refractory status epilepticus is effective. Our experience at @INNNMVS and a systematic review! @DiegoPichardoMD To view: doi.org/10.1002/epd2.7…
🧠 New publication! Super Refractory Status Epilepticus carries a mortality of 25-40%, yet treatment options remain limited. In our systematic review & case series, Vagus Nerve Stimulation was associated with an 87.9% resolution rate. VNS can be considered after 2 weeks of…


Amazing news for all IMGs aspiring to do their residency or research fellowships in the USA!
𝗚𝗼𝗼𝗱 𝗡𝗲𝘄𝘀 𝗙𝗼𝗿 𝗜𝗠𝗚𝘀: 𝗝𝟭 𝗩𝗶𝘀𝗮𝘀 𝗜𝗻𝘁𝗲𝗿𝘃𝗶𝗲𝘄𝘀 𝗮𝗿𝗲 𝗥𝗲𝘀𝘂𝗺𝗶𝗻𝗴 @ECFMG_J1 and @Intealth have officially confirmed via email that J1 visa interviews are resuming—with physicians being prioritized. Great news for IMGs and the U.S. healthcare system!…
Wonderful news to all IMG! j1 visa are being opened again!!
#TBT to a study by Kondziolka et al. (NEJM '98): Stereotactic radiosurgery achieved 98% long-term tumor control for acoustic neuromas, with excellent facial and trigeminal nerve preservation. A pivotal shift toward less invasive neurosurgical care. nejm.org/doi/full/10.10…
Proud to share our latest study! While reoperation at GBM recurrence remains debated, achieving CRET <1cm³ correlates with 46% improved survival vs. partial resection. Standardized volumetric classifications are key to define surgery’s role. Link ⬇️@EsquenaziMD @JNeurooncol
Extremely packed session at the Tumor Soirée by the @NSTumorSection AANS/CNS, bringing together outstanding leaders in neuro-oncology for an engaging discussion. #AANS2025 @AANSNeuro
An honor meeting @NitinAgarwalMD! Thanks for making neurosurgery more approachable for all students. #AANS2025

Keep the faith. As long as you choose to be positive, you’ll rise above all adversity and challenges. There’s always hope!
Fantastic @OU_Neurosurgery representation at #AANS2025! Proud to see so many of our students, residents, & junior faculty getting involved w #E2M in particular 🤓
Honored to be able to work with neurosurgeons who are passionate and constantly pushing the boundaries of their field. Amazing way to kick off #AANS2025! @EsquenaziMD

New publication out now in the Journal of Neuropathology & Experimental Neurology! We show that MTAP immunohistochemistry can serve as a cost-effective marker for CDKN2A deletion in brain tumors (92% Sen, 97% Spe). Great for Meningiomas and Gliomas! A major step toward more…

Excited to share that I’ll be attending #AANS2025 in Boston this year, where I’ll be presenting 7 research abstracts 🧠📊 If you’ll be there too—comment or DM me! I’d love to connect with peers and faculty. Always open to new collaborations and research opportunities. Let’s meet!…